Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Other: Placebo
Drug: Minocycline
Behavioral: Questionnaires

First Posted Date: 2012-07-10

Last Posted Date: 2020-07-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT01636934

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Phase 1

Terminated

Conditions: High Risk Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Azacitidine
Drug: Tosedostat

First Posted Date: 2012-07-10

Last Posted Date: 2020-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT01636609

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Vemurafenib, Carboplatin, and Paclitaxel

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Vemurafenib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2012-07-10

Last Posted Date: 2020-06-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01636622

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cabozantinib
Drug: Androgen Ablation Therapy

First Posted Date: 2012-06-28

Last Posted Date: 2022-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT01630590

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

Phase 1

Terminated

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Biological: Aldesleukin
Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
Biological: Umbilical Cord Blood-Derived Lymphocyte Therapy

First Posted Date: 2012-06-28

Last Posted Date: 2018-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01630564

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage II Non-Small Cell Lung Cancer AJCC v7
Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Non-Small Cell Lung Cancer AJCC v7

Interventions: Radiation: Image Guided Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Radiation: Photon Beam Radiation Therapy
Radiation: Proton Beam Radiation Therapy
Other: Questionnaire Administration

First Posted Date: 2012-06-27

Last Posted Date: 2025-02-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT01629498

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Allogeneic Stem Cell Transplant for CLL

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Richter Syndrome

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Anti-Thymocyte Globulin
Drug: Busulfan
Drug: Clofarabine
Biological: Filgrastim
Drug: Gemcitabine
Drug: Methotrexate
Drug: Tacrolimus

First Posted Date: 2012-06-27

Last Posted Date: 2020-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT01629511

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

Phase 2

Active, not recruiting

Conditions: Sleep Disorder
Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Counseling
Other: Placebo Administration
Drug: Methylphenidate Hydrochloride
Procedure: Phototherapy
Procedure: Sham Intervention
Other: Quality-of-Life Assessment
Drug: Therapeutic Melatonin

First Posted Date: 2012-06-26

Last Posted Date: 2025-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 68

Registration Number: NCT01628029

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Exemestane-RAD001-Metformin

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Everolimus
Drug: Exemestane
Drug: Metformin

First Posted Date: 2012-06-25

Last Posted Date: 2020-06-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT01627067

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Medical Data Collection of Patients With Head and Neck Cancer Treated With Proton Therapy

Active, not recruiting

Conditions: Head and Neck Carcinoma

Interventions: Other: Medical Chart Review
Other: Questionnaire Administration

First Posted Date: 2012-06-25

Last Posted Date: 2025-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 450

Registration Number: NCT01627093

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy